Sage Therapeutics Income Statement

Financials in millions IDR. Fiscal year is January - December.

Millions IDR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	88,479	140,695	247,550	116,750	216,453
Revenue Growth (YoY)	-24.21%	-43.16%	112.03%	-46.06%	-
Cost of Revenue	72,169	113,262	198,422	93,898	197,260
Gross Profit	16,309	27,433	49,128	22,852	19,193
Selling, General & Admin	15,345	14,865	11,534	9,807	7,242
Other Operating Expenses	-677.03	1,711	1,836	-253.49	1,566
Operating Expenses	14,668	16,577	13,370	9,553	8,808
Operating Income	1,641	10,856	35,759	13,299	10,385
Interest Expense	-11.68	-23.36	-91.24	-143.74	-15.52
Interest & Investment Income	700.26	354.27	205.34	251.83	118.09
Currency Exchange Gain (Loss)	28.42	44.89	-6.4	617.32	-305.5
Other Non Operating Income (Expenses)	-9	-11.69	-5.79	-6.69	-5.04
EBT Excluding Unusual Items	2,349	11,220	35,860	14,018	10,177
Gain (Loss) on Sale of Investments	-1,063	-1,063	-	-	-
Gain (Loss) on Sale of Assets	-227.36	-227.36	-28.05	-	-
Pretax Income	1,058	9,930	35,832	14,018	10,177
Income Tax Expense	669.37	3,007	8,508	3,396	2,803
Net Income	389.08	6,923	27,324	10,621	7,374
Net Income to Common	389.08	6,923	27,324	10,621	7,374
Net Income Growth	-96.34%	-74.67%	157.26%	44.05%	-
Shares Outstanding (Basic)	4,769	4,766	4,766	3,644	3,644
Shares Outstanding (Diluted)	4,769	4,766	4,766	3,644	3,644
Shares Change (YoY)	30.89%	-	30.78%	-	-
EPS (Basic)	0.08	1.45	5.73	2.91	2.02
EPS (Diluted)	0.08	1.45	5.73	2.91	2.02
EPS Growth	-97.29%	-74.69%	96.58%	44.05%	-
Free Cash Flow	-136,051	-112,337	7,945	-4,415	12,108
Free Cash Flow Per Share	-28.53	-23.57	1.67	-1.21	3.32
Gross Margin	18.43%	19.50%	19.85%	19.57%	8.87%
Operating Margin	1.85%	7.72%	14.45%	11.39%	4.80%
Profit Margin	0.44%	4.92%	11.04%	9.10%	3.41%
Free Cash Flow Margin	-153.77%	-79.84%	3.21%	-3.78%	5.59%
EBITDA	1,901	11,308	36,182	13,706	10,776
EBITDA Margin	2.15%	8.04%	14.62%	11.74%	4.98%
D&A For EBITDA	259.61	451.65	423.47	406.67	391.24
EBIT	1,641	10,856	35,759	13,299	10,385
EBIT Margin	1.85%	7.72%	14.45%	11.39%	4.80%
Effective Tax Rate	63.24%	30.29%	23.75%	24.23%	27.54%

Updated Sep 18, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.